Progress in determining response to treatment in gastrointestinal stromal tumor.

Progress in determining response to treatment in gastrointestinal stromal tumor.
复制标题

胃肠道间质瘤治疗反应的研究进展。

DOI:
10.1080/14737140.2020.1745068
复制
发表时间:
2020-04
影响因子:
3.3
通讯作者:
Trent, Jonathan C.
Trent, Jonathan C.
中科院分区:
医学3区
文献类型:
--
作者:
Arshad, Junaid;Ahmed, Jibran;Subhawong, Ty;Trent, Jonathan C.

文献摘要

参考文献

被引文献

相似文献

Gastrointestinal stromal tumor (GIST) is the most common malignant mesenchymal tumor of the gastrointestinal system. Multiple advances in the management of GIST from the discovery of KIT/PDGRA and other genetic alterations have led to the development of multiple tyrosine kinase inhibitors. Response assessment in GIST is determined with iRECIST (Response Evaluation Criteria in Solid Tumors), PERCIST (PET response criteria in solid tumors) or Choi criteria. Molecular genotyping of the tissue samples is the recent standard for diagnosis, treatment and response to treatment. Here we provide a brief overview of the history of the GIST, molecular sequencing, available treatment options and clinical trials, radiologic response assessment and the role of ctDNA in response evaluation. Future GIST management is related to the development of sensitive assays to detect genetic alterations for initial diagnosis, treatment selection, monitoring the response to treatment, resistant mutations and predicting survival.
DOI: 10.1097/sla.0b013e3182a15eb7
发表时间: 2013-09
期刊: Annals of surgery
影响因子: 9
作者:
DeMatteo RP;Ballman KV;Antonescu CR;Corless C;Kolesnikova V;von Mehren M;McCarter MD;Norton J;Maki RG;Pisters PW;Demetri GD;Brennan MF;Owzar K;American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology
通讯作者: American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology
DOI: 10.1158/1078-0432.ccr-11-3025
发表时间: 2012-08-15
影响因子: 11.5
作者:
Cassier, Philippe A.;Fumagalli, Elena;Hohenberger, Peter
通讯作者: Hohenberger, Peter
DOI: 10.1634/theoncologist.13-s2-4
发表时间: 2008-01-01
期刊: ONCOLOGIST
影响因子: 5.8
作者:
Choi, Haesun
通讯作者: Choi, Haesun
DOI: 10.1016/s0140-6736(12)61857-1
发表时间: 2013-01-26
期刊: Lancet (London, England)
影响因子: --
作者:
Demetri GD;Reichardt P;Kang YK;Blay JY;Rutkowski P;Gelderblom H;Hohenberger P;Leahy M;von Mehren M;Joensuu H;Badalamenti G;Blackstein M;Le Cesne A;Schöffski P;Maki RG;Bauer S;Nguyen BB;Xu J;Nishida T;Chung J;Kappeler C;Kuss I;Laurent D;Casali PG;GRID study investigators
通讯作者: GRID study investigators
DOI: 10.18632/oncotarget.24268
发表时间: 2018-02-27
期刊: Oncotarget
影响因子: --
作者:
Barris, David M;Weiner, Shoshana B;Weiser, Daniel A
通讯作者: Weiser, Daniel A